Current Report Filing (8-k)
August 09 2019 - 4:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported):
August 7, 2019
InspireMD,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-35731
|
|
26-2123838
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
4
Menorat Hamaor St.
Tel
Aviv, Israel
|
|
6744832
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(888)
776-6804
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
NSPR
|
|
NYSE
American
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
3.01 Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing or Notice of Delisting.
On
August 7, 2019, InspireMD, Inc. (the “Company”) received notification (the “Deficiency Letter”) from the
NYSE American LLC (“NYSE American”) that the Company does not meet continued listing standards of the NYSE American
as set forth in Part 10 of the NYSE American Company Guide (the “Company Guide
”
). Specifically, the
Company is not in compliance with Section 1003(a)(iii) of the Company Guide because the Company reported stockholders’ equity
of less than $6 million as of June 30, 2019, and net losses in its five most recent fiscal years ended December 31, 2018. As a
result, the Company has become subject to the procedures and requirements of Section 1009 of the Company Guide.
The
Company must submit a plan of compliance to NYSE Regulation by September 6, 2019, addressing how it intends to regain compliance
with Section 1003(a)(iii) of the Company Guide by August 7, 2020. If the plan is accepted by NYSE Regulation, the Company may
be able to continue its listing during the plan period, during which time the Company will be subject to periodic review to determine
whether it is making progress consistent with the plan.
If
the Company does not submit a plan, or if the plan is not accepted by NYSE Regulation, delisting proceedings will commence. Furthermore,
if the plan is accepted but the Company is not in compliance with the continued listing standards by August 7, 2020, or if it
does not make progress consistent with the plan during the plan period, the NYSE American will initiate delisting proceedings.
The
Company’s management is reviewing its options to address the deficiencies and expects to submit a compliance plan on or
before the deadline set by the NYSE American.
Item
8.01 Other Events.
On
August 9, 2019, the Company issued a press release disclosing receipt of the Deficiency Letter from the NYSE American. A copy
of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
InspireMD
Inc.
|
|
|
|
Date:
August 9, 2019
|
By:
|
/s/
Craig Shore
|
|
Name:
|
Craig
Shore
|
|
Title:
|
Chief
Financial Officer
|
InspireMD (AMEX:NSPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
InspireMD (AMEX:NSPR)
Historical Stock Chart
From Sep 2023 to Sep 2024